BACKGROUND: Lipid rafts are cholesterol-enriched microdomains in cell membranes that have been shown to regulate signal transduction. We investigated whether membrane cholesterol could regulate apoptosis and attempted to elucidate the mechanism by which apoptosis is induced in prostate cancer cells. METHODS: LNCaP cells were exposed to 2-hydroxyprophyl-beta-cyclodextrin (HPCD) to deplete membrane cholesterol. Cell viability and apoptosis were evaluated by Celltiter Bluetrade mark Cell Viability assay and ethidium bromide/acridine orange staining. Signal transduction was investigated by immunoblot analysis of cell lysates. RESULTS: Cell viability was dose dependent inhibited by HPCD and restored by replenishment of cholesterol. HPCD induced apoptotic cell death through down-regulation of Bcl-xL and up-regulation of caspase-3 and PARP cleavages. HPCD inhibited both EGFR/Akt and EGFR/ERK signal transduction. CONCLUSIONS: Lipid raft cholesterol regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK pathways.
BACKGROUND:Lipid rafts are cholesterol-enriched microdomains in cell membranes that have been shown to regulate signal transduction. We investigated whether membrane cholesterol could regulate apoptosis and attempted to elucidate the mechanism by which apoptosis is induced in prostate cancer cells. METHODS: LNCaP cells were exposed to 2-hydroxyprophyl-beta-cyclodextrin (HPCD) to deplete membrane cholesterol. Cell viability and apoptosis were evaluated by Celltiter Bluetrade mark Cell Viability assay and ethidium bromide/acridine orange staining. Signal transduction was investigated by immunoblot analysis of cell lysates. RESULTS: Cell viability was dose dependent inhibited by HPCD and restored by replenishment of cholesterol. HPCD induced apoptotic cell death through down-regulation of Bcl-xL and up-regulation of caspase-3 and PARP cleavages. HPCD inhibited both EGFR/Akt and EGFR/ERK signal transduction. CONCLUSIONS:Lipid raft cholesterol regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK pathways.
Authors: Yoshitaka Sekine; Steve J Demosky; John A Stonik; Yosuke Furuya; Hidekazu Koike; Kazuhiro Suzuki; Alan T Remaley Journal: Mol Cancer Res Date: 2010-07-29 Impact factor: 5.852
Authors: Byron H Lee; Margaret G Taylor; Peggy Robinet; Jonathan D Smith; Jessica Schweitzer; Ephraim Sehayek; Sara M Falzarano; Cristina Magi-Galluzzi; Eric A Klein; Angela H Ting Journal: Cancer Res Date: 2012-12-11 Impact factor: 12.701
Authors: Jeriel T R Keeney; Aaron M Swomley; Sarah Förster; Jessica L Harris; Rukhsana Sultana; D Allan Butterfield Journal: Proteomics Clin Appl Date: 2013-01 Impact factor: 3.494
Authors: Shahar Robinzon; Avis Dafa-Berger; Mathew D Dyer; Bryan Paeper; Sean C Proll; Thomas H Teal; Slava Rom; Daniel Fishman; Bracha Rager-Zisman; Michael G Katze Journal: J Virol Date: 2009-03-18 Impact factor: 5.103
Authors: Mauricio G Martin; Simona Perga; Laura Trovò; Andrea Rasola; Pontus Holm; Tomi Rantamäki; Tibor Harkany; Eero Castrén; Federica Chiara; Carlos G Dotti Journal: Mol Biol Cell Date: 2008-02-20 Impact factor: 4.138